ClinicalTrials.gg
Sign In
RecruitingNCT07783425TilrekUpdated Nov 6, 2026

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

A Phase 3 interventional study of Tilrekimig and Dupilumab in Atopic Dermatitis, sponsored by Pfizer. Recruiting at 50 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 6, 2026Now RecruitingFirst sites in Japan, Canada and Taiwan+6 moreGo to Updates ↓
Phase
Phase 3
Study type
Interventional
Enrollment
1,375
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema is a condition which can cause dryness, itching, and redness of your skin.

The study is seeking participants who:

  • Are aged 12 years or older.
  • Were confirmed to have atopic dermatitis (AD) at least 12 months ago.
  • Are not having an effective treatment result from medicines that are applied on skin for AD.
  • Are considered by their doctors to have moderate to severe AD.

The study treatment period will be 52 weeks. During the 24-week initial treatment period, participants will be randomized to one of three study treatments - tilrekimig, dupilumab, or placebo. Placebo does not have any medicine in it but looks just like the medicine being studied. These treatments will be randomized based on a 2:2:1 ratio. This means out of 1375 participants, about 550 participants will receive tilrekimig, 550 will receive dupilumab, and 275 will receive placebo. This will be followed by a 28-week maintenance period. The last dose of study treatment will be administered at week 48.

Some participants will join the long-term extension (LTE) study C4531008 at week 52. A long-term extension study is an additional study that some participants may be able to join after completing the study if they are interested and meet eligibility requirements. It allows researchers to continue collecting information about how well the study medicine works. It also helps them assess how safe it is when used for a longer period of time. Participants who do not join this study will enter a 12-week safety follow-up period. This period ends 16 weeks after their last dose of study treatment.

02

Conditions studied

  • Atopic Dermatitis

Keywords

  • Immune system diseases
  • skin diseases, genetic
  • eczema
  • atopic dermatitis
  • Dermatitis
  • skin diseases
  • Skin Diseases, Eczematous
03

In context

Dermatitis, Atopic

1,591 studies on the registry are indexed under Dermatitis, Atopic; 286 are open to participants now.

This study's planned enrollment of 1,375 is above the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.

Browse Dermatitis, Atopic studies →

Lead sponsor

Pfizer is the lead sponsor of 3,334 studies on the registry; 149 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 391 (65%) have results posted.

Browse Pfizer studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  • You are [12] years of age or older
  • You have had moderate-to-severe eczema for at least 1 year
  • Topical medicines for eczema have not worked well for you

Key Exclusion Criteria

  • Disease
  • Significant Infection History or Active Infection
  • Known or Suspected Immunodeficiency/
  • Significant psychiatric illness or suicidality
  • Clinically significant hepatic, renal, or hematologic abnormalities
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,375 participants (estimated)

Study arms

  • Experimental
    Tilrekimig - Initial treatment period

    Subcutaneous injections given over 20 Weeks.

    Drug: Tilrekimig

  • Placebo comparator
    Placebo - Initial treatment period

    Subcutaneous injections given over 22 Weeks.

    Other: Placebo for Tilrekimig · Other: Placebo for Dupilumab

  • Experimental
    Tilrekimig - Maintenance Period - Dose B

    Subcutaneous injections given at Week 24 through Week 48.

    Drug: Tilrekimig

  • Experimental
    Tilrekimig - Maintenance Period - Dose A

    Subcutaneous injections given at Week 24 through Week 48.

    Drug: Tilrekimig

  • Active comparator
    Dupilumab - Initial treatment period

    Subcutaneous injections given over 22 Weeks.

    Drug: Dupilumab

  • Placebo comparator
    Placebo - Maintenance Period

    Subcutaneous injections given at Week 24 through Week 48.

    Other: Placebo for Tilrekimig · Other: Placebo for Dupilumab

Interventions

  • DrugTilrekimig

    Subcutaneous Injections at required timepoints

    Also known as: PF-07275315

  • DrugDupilumab

    Subcutaneous Injections at required timepoints based on weight and age.

    Also known as: Dupixent

  • OtherPlacebo for Tilrekimig

    Subcutaneous Injections at required timepoints

    Also known as: Placebo for PF-07275315

  • OtherPlacebo for Dupilumab

    Subcutaneous Injections at required timepoints during initial treatment period.

06

What researchers measure

Primary outcomes

  1. Difference in the proportion of Eczema Area and Severity Index (EASI)75 responders between tilrekimig versus placebo.

    Time frame: Week 16

  2. Difference in the proportion of validated Investigator Global Assessment- Atopic Dermatitis (vIGA-AD) 0/1 responders between tilrekimig versus placebo.

    Time frame: Week 16

Secondary outcomes

  1. Difference in the proportion of Peak Pruritis Numerical Rating Score (PP-NRS)4 responders between tilrekimig versus placebo

    Time frame: Week 1 through Week 24

  2. Difference in the proportion of PP-NRS4 responders between tilrekimig versus dupilumab

    Time frame: Week 1 through Week 24

  3. Incidence of treatment emergent adverse events (AEs), Serious adverse events (SAEs), and AEs leading to discontinuation

    Time frame: For each participant from the time the participant provides informed consent, through and including a minimum of 16 weeks after the last administration of the study intervention.

  4. Incidence of clinically significant changes in vital signs and laboratory tests.

    Time frame: For each participant following first administration of the study intervention through the end of study visit (week 64).

  5. Difference in the proportion of Eczema Area and Severity Index (EASI)75 responders between tilrekimig versus placebo.

    Time frame: Weeks 2, 4, 8, 12, 14, 20, and 24

  6. Difference in the proportion of Eczema Area and Severity Index (EASI)75 responders between tilrekimig versus dupilumab.

    Time frame: Weeks 2, 4, 8, 12, 14, 16, 20, and 24

  7. Difference in the proportion of validated Investigator Global Assessment- Atopic Dermatitis (vIGA-AD) 0/1 responders between tilrekimig versus placebo.

    Time frame: Weeks 2, 4, 8, 12, 14, 20, and 24

  8. Difference in the proportion of validated Investigator Global Assessment- Atopic Dermatitis (vIGA-AD) 0/1 responders between tilrekimig versus dupilumab.

    Time frame: Weeks 2, 4, 8, 12, 14, 16, 20, and 24

  9. Difference in the proportion of revised Global Investigator Assessment (rIGA) 0/1 responders between tilrekimig versus placebo.

    Time frame: Weeks 2, 4, 8, 12, 14, 16, 20, and 24

  10. Difference in the proportion of revised Global Investigator Assessment (rIGA) 0/1 responders between tilrekimig versus dupilumab.

    Time frame: Weeks 2, 4, 8, 12, 14, 16, 20, and 24

  11. Difference in the proportion of EASI50, EASI90, and EASI100 responders between tilrekimig versus placebo.

    Time frame: Weeks 2, 4, 8, 12, 14, 16, 20 and 24

  12. Difference in the proportion of EASI50, EASI90, and EASI100 responders between tilrekimig versus dupilumab.

    Time frame: Weeks 2, 4, 8, 12, 14, 16, 20 and 24

  13. Difference in the mean percent CFB in EASI total score between tilrekimig versus placebo.

    Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24

  14. Difference in the mean percent CFB in EASI total score between tilrekimig versus dupilumab.

    Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24

  15. Difference in the mean percent CFB in Body Surface Area (BSA) between tilrekimig versus placebo.

    Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24

  16. Difference in the mean percent CFB in Body Surface Area (BSA) between tilrekimig versus dupilumab.

    Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24

  17. Difference in the proportion of Patient Oriented Eczema Measure (POEM) responders achieving ≥4-point improvement from baseline between tilrekimig versus placebo.

    Time frame: Weeks 8, 16, and 24

  18. Difference in the proportion of POEM responders achieving ≥4-point improvement from baseline between tilrekimig versus dupilumab.

    Time frame: Weeks 8, 16, and 24

  19. Difference in the proportion of Dermatology Life Quality Index (DLQI) responders achieving ≥4-point improvement from baseline between tilrekimig versus placebo.

    Time frame: Weeks 8, 16, and 24

  20. Difference in the proportion of Dermatology Life Quality Index (DLQI) responders achieving ≥4-point improvement from baseline between tilrekimig versus dupilumab

    Time frame: Weeks 8, 16, and 24

  21. Difference in the proportion of Patient Global Impression of Severity (PGI-S) responders achieving a score of 0 or 1 between tilrekimig versus placebo.

    Time frame: Weeks 8, 16, and 24

  22. Difference in the proportion of Patient Global Impression of Severity (PGI-S) responders achieving a score of 0 or 1 between tilrekimig versus dupilumab.

    Time frame: Weeks 8, 16, and 24

  23. Difference in the proportion of Patient Global Impression of Change (PGI-C) responders achieving "Much better" between tilrekimig versus placebo.

    Time frame: Weeks 8, 16, and 24

  24. Difference in the proportion of Patient Global Impression of Change (PGI-C) responders achieving "Much better" between tilrekimig versus dupilumab.

    Time frame: Weeks 8, 16, and 24

  25. Difference in the proportion of Atopic Dermatitis Control Tool (ADCT) responders achieving ≥5-point improvement from baseline between tilrekimig versus placebo.

    Time frame: Weeks 8, 16, and 24

  26. Difference in the proportion of Atopic Dermatitis Control Tool (ADCT) responders achieving ≥5-point improvement from baseline between tilrekimig versus dupilumab.

    Time frame: Weeks 8, 16, and 24

  27. Difference in the mean percent CFB in POEM between tilrekimig versus placebo.

    Time frame: Weeks 8, 16, and 24

  28. Difference in the mean percent CFB in EASI total score between tilrekimig versus dupilumab.

    Time frame: Weeks 8, 16, and 24

  29. Difference in the mean percent CFB in DLQI between tilrekimig versus placebo.

    Time frame: Weeks 8, 16, and 24

  30. Difference in the mean percent CFB in DLQI between tilrekimig versus dupilumab.

    Time frame: Weeks 8, 16, and 24

  31. Difference in the mean percent CFB in Children's Dermatology Life Quality Index (CDLQI) between tilrekimig versus placebo.

    Time frame: Weeks 8, 16, and 24

  32. Difference in the mean percent CFB in CDLQI between tilrekimig versus dupilumab.

    Time frame: Weeks 8, 16, and 24

  33. Difference in the mean percent CFB in PP-NRS weekly average between tilrekimig versus placebo.

    Time frame: Week 1 through week 24

  34. Difference in the mean percent CFB in PP-NRS weekly average between tilrekimig versus dupilumab.

    Time frame: Week 1 through Week 24

  35. Proportion of responders for EASI75, rIGA 0/1, vIGA-AD 0, PP-NRS4, EASI50, EASI90, and EASI100 for tilrekimig doses and placebo.

    Time frame: Weeks 26, 28, 32, 36, 40, 44, 48, 52, and 64

  36. Mean of percent CFB in EASI and BSA for tilrekimig doses and placebo

    Time frame: Weeks 26, 28, 32, 36, 40, 44, 48, 52, and 64

  37. Proportion of maintaining response at Week 52 (defined as meeting ≥50% improvement from baseline in EASI and vIGA-AD <3) for participants who responded to tilrekimig (defined as achieving either EASI75 or vIGA-ADTM 0/1 at Week 24).

    Time frame: Week 52

  38. The proportion of POEM responders achieving ≥4-point improvement from baseline for tilrekimig doses and placebo.

    Time frame: Weeks 28, 36, 44, 52, and 64

  39. The proportion of DLQI responders achieving ≥4-point improvement from baseline for tilrekimig doses and placebo.

    Time frame: Weeks 28, 36, 44, 52, and 64

  40. The proportion of PGI-S responders achieving a score of 0 or 1 for tilrekimig doses and placebo.

    Time frame: Weeks 28, 36, 44, 52, and 64

  41. The proportion of PGI-C responders achieving "Much better" for tilrekimig doses and placebo.

    Time frame: Weeks 28, 36, 44, 52, and 64

  42. The proportion of ADCT responders achieving ≥5-point improvement from baseline for tilrekimig doses and placebo.

    Time frame: Weeks 28, 36, 44, 52, and 64

  43. Mean of CFB in POEM, DLQI, and CDLQI for tilrekimig doses and placebo.

    Time frame: Weeks 28, 36, 44, 52, and 64

  44. Mean of CFB in weekly averages of PP=NRS for tilrekimig doses and placebo.

    Time frame: Weeks 26, 28, 32, 36, 40, 44, 48, 52, and 64

07

Study locations

31 of 50 sites recruiting
  • AllerVie Clinical Research
    Birmingham, Alabama 35209, United States
    Recruiting
  • Cahaba Dermatology & Skin Health Center
    Birmingham, Alabama 35244, United States
    Not yet recruiting
  • Alliance Dermatology & MOHS Center
    Phoenix, Arizona 85032, United States
    Recruiting
  • Dermatology Trial Associates, Inc.
    Bryant, Arkansas 72022, United States
    Recruiting
  • Kern Research, Inc.
    Bakersfield, California 93301, United States
    Recruiting
  • First OC Dermatology Research Inc
    Fountain Valley, California 92708, United States
    Not yet recruiting
  • Marvel Clinical Research
    Huntington Beach, California 92647, United States
    Recruiting
  • Avance Clinical Trials
    Laguna Niguel, California 92677, United States
    Recruiting
  • California Allergy & Asthma Medical Group
    Los Angeles, California 90025, United States
    Recruiting
  • Northridge Clinical Trials, LLC
    Northridge, California 91325, United States
    Recruiting
  • Wolverine Clinical Trials
    Santa Ana, California 92706, United States
    Not yet recruiting
  • Direct Helpers Research Center
    Hialeah, Florida 33012, United States
    Recruiting
  • Research Associates of South Florida, LLC
    Miami, Florida 33134, United States
    Recruiting
  • Global Health Research Center, Inc.
    Miami Lakes, Florida 33016, United States
    Recruiting
  • Clinical Neuroscience Solutions, LLC
    Orlando, Florida 32801, United States
    Recruiting
  • Advanced Clinical Research Institute
    Tampa, Florida 33607, United States
    Not yet recruiting
  • Skin Care Physicians of Georgia
    Macon, Georgia 31217, United States
    Recruiting
  • Marietta Dermatology Clinical Research, Inc.
    Marietta, Georgia 30060, United States
    Recruiting
  • Treasure Valley Medical Research
    Boise, Idaho 83706, United States
    Not yet recruiting
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
    Recruiting
  • Maryland Laser Skin and Vein
    Hunt Valley, Maryland 21030, United States
    Recruiting
  • Revival Research Institute, LLC
    Troy, Michigan 48084, United States
    Not yet recruiting
  • Respiratory Medicine Research Institute of Michigan, PLC
    Ypsilanti, Michigan 48197, United States
    Recruiting
  • Empire Dermatology
    East Syracuse, New York 13057, United States
    Not yet recruiting
  • Vital Prospects Clinical Research Institute., PC
    Tulsa, Oklahoma 74136, United States
    Recruiting
  • Oregon Medical Research Center
    Portland, Oregon 97201, United States
    Not yet recruiting
  • Best Skin Research, LLC
    Camp Hill, Pennsylvania 17011, United States
    Not yet recruiting
  • Clinical Neuroscience Solutions, LLC.
    Memphis, Tennessee 38119, United States
    Recruiting
  • Arlington Research Center
    Arlington, Texas 76011, United States
    Recruiting
  • Dermatology Treatment and Research Center
    Dallas, Texas 75230, United States
    Recruiting
  • Derm Texas
    Dallas, Texas 75235, United States
    Recruiting
  • Stryde Research-Epiphany Dermatology
    Southlake, Texas 76092, United States
    Not yet recruiting
  • Complete Dermatology
    Sugar Land, Texas 77479, United States
    Recruiting
  • Alexandria Associates in Dermatology
    Arlington, Virginia 22206, United States
    Recruiting
  • Innovaderm Research Inc
    Montreal, Quebec H2X 2V1, Canada
    Not yet recruiting
  • Japan Community Healthcare Organization Chukyo Hospital
    Nagoya, Aichi-ken 457-8510, Japan
    Not yet recruiting
  • Iwate Medical University Hospital
    Yahaba-cho, Iwate 028-3695, Japan
    Not yet recruiting
  • Queen's Square Medical Facilities Queen's Square Medical Center, Dermatology and Allergology
    Yokohama, Kanagawa 220-6208, Japan
    Recruiting
  • Osaka Habikino Medical Center
    Habikino, Osaka 583-8588, Japan
    Recruiting
  • Izumigaoka Skin Clinic
    Sakai, Osaka 590-0111, Japan
    Not yet recruiting
  • Dermatology and Ophthalmology Kume Clinic
    Sakai, Osaka 593-8324, Japan
    Recruiting
  • Dokkyo Medical University Hospital
    Shimotsuga-gun, Tochigi 321-0293, Japan
    Not yet recruiting
  • Nihonbashi Sakura Clinic
    Chuo-ku, Tokyo 103-0025, Japan
    Recruiting
  • Fukuwa Clinic
    Chuo-ku, Tokyo 104-0031, Japan
    Not yet recruiting
  • Tachikawa Dermatology Clinic
    Tachikawa, Tokyo 190-0023, Japan
    Recruiting
  • Ikebukuro-nishiguchi Fukurou Dermatology Clinic
    Toshima-ku, Tokyo 171-0021, Japan
    Recruiting
  • Katahira Dermatology Urology Clinic
    Kagoshima, 890-0063, Japan
    Recruiting
  • Okayama University Hospital
    Okayama, 700-8558, Japan
    Not yet recruiting
  • Pansy Skin Clinic
    Saitama, 330-0064, Japan
    Not yet recruiting
  • China Medical University Hospital
    Taichung, 40447, Taiwan
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.

Of 149 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 24 months is above that.

Counting every sponsor, half of 156 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2028 → Sep 2028, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2026
First posted
Aug 24, 2026
StartActual
Aug 24, 2026
Primary completionEst.
Sep 8, 2028was Aug 2028
CompletionEst.
Jun 15, 2029
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 6, 2026
Sites
51 sites added, 2 sites removed — first sites in Japan, Canada and Taiwan. 15 sites changed recruiting status (15 now recruiting)
Show 15 sites
  • Vital Prospects Clinical Research Institute., PC · Tulsa, United Statesno status→Recruiting
  • Respiratory Medicine Research Institute of Michigan, PLC · Ypsilanti, United StatesNot yet recruiting→Recruiting
  • Dermatology Treatment and Research Center · Dallas, United StatesNot yet recruiting→Recruiting
  • Complete Dermatology · Sugar Land, United StatesNot yet recruiting→Recruiting
  • Alliance Dermatology & MOHS Center · Phoenix, United StatesNot yet recruiting→Recruiting
  • California Allergy & Asthma Medical Group · Los Angeles, United StatesNot yet recruiting→Recruiting
  • Maryland Laser Skin and Vein · Hunt Valley, United StatesNot yet recruiting→Recruiting
  • Alexandria Associates in Dermatology · Arlington, United StatesNot yet recruiting→Recruiting
  • Queen's Square Medical Facilities Queen's Square Medical Center, Dermatology and Allergology · Yokohama, JapanNot yet recruiting→Recruiting
  • Osaka Habikino Medical Center · Habikino, JapanNot yet recruiting→Recruiting
  • Dermatology and Ophthalmology Kume Clinic · Sakai, JapanNot yet recruiting→Recruiting
  • Nihonbashi Sakura Clinic · Chuo-ku, JapanNot yet recruiting→Recruiting
  • Tachikawa Dermatology Clinic · Tachikawa, JapanNot yet recruiting→Recruiting
  • Ikebukuro-nishiguchi Fukurou Dermatology Clinic · Toshima-ku, JapanNot yet recruiting→Recruiting
  • Katahira Dermatology Urology Clinic · Kagoshima, JapanNot yet recruiting→Recruiting
Show 51 added (33 United States, 16 Japan, 1 Canada, 1 Taiwan)
  • Alliance Dermatology & MOHS Center · Phoenix, United States
  • Marvel Clinical Research · Huntington Beach, United States
  • Northridge Clinical Trials, LLC · Northridge, United States
  • Marietta Dermatology Clinical Research, Inc. · Marietta, United States
  • Dawes Fretzin Clinical Research Group, LLC · Indianapolis, United States
  • Revival Research Institute, LLC · Troy, United States
  • Respiratory Medicine Research Institute of Michigan, PLC · Ypsilanti, United States
  • Best Skin Research, LLC · Camp Hill, United States
  • Clinical Neuroscience Solutions, LLC. · Memphis, United States
  • Dermatology Treatment and Research Center · Dallas, United States
  • Complete Dermatology · Sugar Land, United States
  • Japan Community Healthcare Organization Chukyo Hospital · Nagoya, Japan
  • Katahira Dermatology Urology Clinic · Kagoshima, Japan
  • Queen's Square Medical Facilities Queen's Square Medical Center, Dermatology and Allergology · Yokohama, Japan
  • Izumigaoka Skin Clinic · Sakai, Japan
  • Dermatology and Ophthalmology Kume Clinic · Sakai, Japan
  • Pansy Skin Clinic · Saitama, Japan
  • Nihonbashi Sakura Clinic · Chuo-ku, Japan
  • Fukuwa Clinic · Chuo-ku, Japan
  • Tachikawa Dermatology Clinic · Tachikawa, Japan
  • Ikebukuro-nishiguchi Fukurou Dermatology Clinic · Toshima-ku, Japan
  • Dermatology Trial Associates, Inc. · Bryant, United States
  • California Allergy & Asthma Medical Group · Los Angeles, United States
  • Clinical Neuroscience Solutions, LLC · Orlando, United States
  • Treasure Valley Medical Research · Boise, United States
  • Maryland Laser Skin and Vein · Hunt Valley, United States
  • Derm Texas · Dallas, United States
  • Stryde Research-Epiphany Dermatology · Southlake, United States
  • Alexandria Associates in Dermatology · Arlington, United States
  • Osaka Habikino Medical Center · Habikino, Japan
  • …and 21 more on the registry record
Show 2 removed
  • Katahira Dermatology Urology Clinic · Kagoshima, Japan
  • Pansy Skin Clinic · Saitama, Japan
across 3 updates, Oct 6, 2026 – Nov 6, 2026
Start date
Aug 19, 2026→Aug 24, 2026 (actual)
Oct 6, 2026
Primary completion
Aug 29, 2028→Sep 8, 2028
Oct 6, 2026
Study completion
Jun 5, 2029→Jun 15, 2029
Oct 6, 2026
Show all 3 updates
  1. Nov 6, 2026
    18 sites added — first sites in Canada and Taiwan. 11 sites changed recruiting status (11 now recruiting)
    Show 11 sites
    • Alliance Dermatology & MOHS Center · Phoenix, United StatesNot yet recruiting→Recruiting
    • California Allergy & Asthma Medical Group · Los Angeles, United StatesNot yet recruiting→Recruiting
    • Maryland Laser Skin and Vein · Hunt Valley, United StatesNot yet recruiting→Recruiting
    • Alexandria Associates in Dermatology · Arlington, United StatesNot yet recruiting→Recruiting
    • Queen's Square Medical Facilities Queen's Square Medical Center, Dermatology and Allergology · Yokohama, JapanNot yet recruiting→Recruiting
    • Osaka Habikino Medical Center · Habikino, JapanNot yet recruiting→Recruiting
    • Dermatology and Ophthalmology Kume Clinic · Sakai, JapanNot yet recruiting→Recruiting
    • Nihonbashi Sakura Clinic · Chuo-ku, JapanNot yet recruiting→Recruiting
    • Tachikawa Dermatology Clinic · Tachikawa, JapanNot yet recruiting→Recruiting
    • Ikebukuro-nishiguchi Fukurou Dermatology Clinic · Toshima-ku, JapanNot yet recruiting→Recruiting
    • Katahira Dermatology Urology Clinic · Kagoshima, JapanNot yet recruiting→Recruiting
    Show 18 added (14 United States, 2 Japan, 1 Canada, 1 Taiwan)
    • AllerVie Clinical Research · Birmingham, United States
    • Cahaba Dermatology & Skin Health Center · Birmingham, United States
    • Kern Research, Inc. · Bakersfield, United States
    • First OC Dermatology Research Inc · Fountain Valley, United States
    • Avance Clinical Trials · Laguna Niguel, United States
    • Wolverine Clinical Trials · Santa Ana, United States
    • Direct Helpers Research Center · Hialeah, United States
    • Research Associates of South Florida, LLC · Miami, United States
    • Global Health Research Center, Inc. · Miami Lakes, United States
    • Advanced Clinical Research Institute · Tampa, United States
    • Skin Care Physicians of Georgia · Macon, United States
    • Empire Dermatology · East Syracuse, United States
    • Oregon Medical Research Center · Portland, United States
    • Arlington Research Center · Arlington, United States
    • Innovaderm Research Inc · Montreal, Canada
    • Iwate Medical University Hospital · Yahaba-cho, Japan
    • Dokkyo Medical University Hospital · Shimotsuga-gun, Japan
    • China Medical University Hospital · Taichung, Taiwan
    + 1 other change: verification date
  2. Oct 22, 2026
    12 sites added, 2 sites removed. 3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Respiratory Medicine Research Institute of Michigan, PLC · Ypsilanti, United StatesNot yet recruiting→Recruiting
    • Dermatology Treatment and Research Center · Dallas, United StatesNot yet recruiting→Recruiting
    • Complete Dermatology · Sugar Land, United StatesNot yet recruiting→Recruiting
    Show 12 added (8 United States, 4 Japan)
    • Dermatology Trial Associates, Inc. · Bryant, United States
    • California Allergy & Asthma Medical Group · Los Angeles, United States
    • Clinical Neuroscience Solutions, LLC · Orlando, United States
    • Treasure Valley Medical Research · Boise, United States
    • Maryland Laser Skin and Vein · Hunt Valley, United States
    • Derm Texas · Dallas, United States
    • Stryde Research-Epiphany Dermatology · Southlake, United States
    • Alexandria Associates in Dermatology · Arlington, United States
    • Osaka Habikino Medical Center · Habikino, Japan
    • Katahira Dermatology Urology Clinic · Kagoshima, Japan
    • Okayama University Hospital · Okayama, Japan
    • Pansy Skin Clinic · Saitama, Japan
    Show 2 removed
    • Katahira Dermatology Urology Clinic · Kagoshima, Japan
    • Pansy Skin Clinic · Saitama, Japan
  3. Oct 6, 2026
    Not yet recruiting→Recruiting
    21 sites added — first site in Japan. Vital Prospects Clinical Research Institute., PC is now Recruiting
    Show 21 added (11 United States, 10 Japan)
    • Alliance Dermatology & MOHS Center · Phoenix, United States
    • Marvel Clinical Research · Huntington Beach, United States
    • Northridge Clinical Trials, LLC · Northridge, United States
    • Marietta Dermatology Clinical Research, Inc. · Marietta, United States
    • Dawes Fretzin Clinical Research Group, LLC · Indianapolis, United States
    • Revival Research Institute, LLC · Troy, United States
    • Respiratory Medicine Research Institute of Michigan, PLC · Ypsilanti, United States
    • Best Skin Research, LLC · Camp Hill, United States
    • Clinical Neuroscience Solutions, LLC. · Memphis, United States
    • Dermatology Treatment and Research Center · Dallas, United States
    • Complete Dermatology · Sugar Land, United States
    • Japan Community Healthcare Organization Chukyo Hospital · Nagoya, Japan
    • Katahira Dermatology Urology Clinic · Kagoshima, Japan
    • Queen's Square Medical Facilities Queen's Square Medical Center, Dermatology and Allergology · Yokohama, Japan
    • Izumigaoka Skin Clinic · Sakai, Japan
    • Dermatology and Ophthalmology Kume Clinic · Sakai, Japan
    • Pansy Skin Clinic · Saitama, Japan
    • Nihonbashi Sakura Clinic · Chuo-ku, Japan
    • Fukuwa Clinic · Chuo-ku, Japan
    • Tachikawa Dermatology Clinic · Tachikawa, Japan
    • Ikebukuro-nishiguchi Fukurou Dermatology Clinic · Toshima-ku, Japan
    Start date Aug 19, 2026→Aug 24, 2026 (now actual)
    Primary completion Aug 29, 2028→Sep 8, 2028
    Study completion Jun 5, 2029→Jun 15, 2029
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07783425
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 24, 2026
Start date
Aug 24, 2026
Primary completion
Sep 8, 2028 (estimated)
Completion
Jun 15, 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tilrekimig

Other studies in this condition

Dermatitis, Atopic →

Other studies from this sponsor

Pfizer →

Start the discussion